drugset / Trial / NCT00002226

Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

NCT00002226 ↗

Completed 30 enrolled SUGEN
Treatment

Summary

The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.

Timeline

Start
—
Primary completion
—
Completion
—

Publications

  • Background Gill P, Arasteh K, Jacobs M, Friedman-Kiel A, Miles S, Gracey S, Hannah A, Langecker P. A multicenter, dose-escalating study in patients with AIDS-related Kaposi's Sarcoma 39th Intersci Conf Antimicrob Agents Chemother. 1999 Sept 26-29

Drugs

EvaluationDrugModalityDoseRoute
Subject semaxanib Small molecule — Intravenous